|
US4741900A
(en)
|
1982-11-16 |
1988-05-03 |
Cytogen Corporation |
Antibody-metal ion complexes
|
|
GB8308235D0
(en)
|
1983-03-25 |
1983-05-05 |
Celltech Ltd |
Polypeptides
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US5807715A
(en)
|
1984-08-27 |
1998-09-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
|
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
|
AU600575B2
(en)
|
1987-03-18 |
1990-08-16 |
Sb2, Inc. |
Altered antibodies
|
|
EP0428534B1
(en)
|
1988-06-14 |
1995-03-29 |
Cetus Oncology Corporation |
Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
|
|
US6780613B1
(en)
|
1988-10-28 |
2004-08-24 |
Genentech, Inc. |
Growth hormone variants
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
ZA902949B
(en)
|
1989-05-05 |
1992-02-26 |
Res Dev Foundation |
A novel antibody delivery system for biological response modifiers
|
|
US5460785A
(en)
|
1989-08-09 |
1995-10-24 |
Rhomed Incorporated |
Direct labeling of antibodies and other protein with metal ions
|
|
GB8928874D0
(en)
|
1989-12-21 |
1990-02-28 |
Celltech Ltd |
Humanised antibodies
|
|
US5314995A
(en)
|
1990-01-22 |
1994-05-24 |
Oncogen |
Therapeutic interleukin-2-antibody based fusion proteins
|
|
EP0521985B1
(en)
|
1990-03-20 |
1997-09-24 |
The Trustees Of Columbia University In The City Of New York |
Chimeric antibodies with receptor binding ligands in place of their constant region
|
|
ES2178635T3
(es)
|
1990-11-09 |
2003-01-01 |
Stephen D Gillies |
Inmunoconjugados de citoquinas.
|
|
DE69233482T2
(de)
|
1991-05-17 |
2006-01-12 |
Merck & Co., Inc. |
Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
|
|
ES2136092T3
(es)
|
1991-09-23 |
1999-11-16 |
Medical Res Council |
Procedimientos para la produccion de anticuerpos humanizados.
|
|
US5817310A
(en)
|
1991-12-02 |
1998-10-06 |
Cor Therapeutics, Inc. |
Inhibitory immunoglobulin polypeptides to human PDGF beta receptor
|
|
DE69233125T2
(de)
*
|
1991-12-02 |
2004-04-22 |
Millennium Pharmaceuticals, Inc., South San Francisco |
Inhibitorische immunglobulin-polypeptide gegen den pdgf beta-rezeptor
|
|
US5639641A
(en)
|
1992-09-09 |
1997-06-17 |
Immunogen Inc. |
Resurfacing of rodent antibodies
|
|
US5922545A
(en)
|
1993-10-29 |
1999-07-13 |
Affymax Technologies N.V. |
In vitro peptide and antibody display libraries
|
|
GB9422383D0
(en)
|
1994-11-05 |
1995-01-04 |
Wellcome Found |
Antibodies
|
|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US5739277A
(en)
|
1995-04-14 |
1998-04-14 |
Genentech Inc. |
Altered polypeptides with increased half-life
|
|
US6096871A
(en)
|
1995-04-14 |
2000-08-01 |
Genentech, Inc. |
Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
GB9524973D0
(en)
|
1995-12-06 |
1996-02-07 |
Lynxvale Ltd |
Viral vectors
|
|
WO1998005787A1
(en)
|
1996-08-02 |
1998-02-12 |
Bristol-Myers Squibb Company |
A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
|
|
WO1998023289A1
(en)
|
1996-11-27 |
1998-06-04 |
The General Hospital Corporation |
MODULATION OF IgG BINDING TO FcRn
|
|
ATE529509T1
(de)
|
1997-01-21 |
2011-11-15 |
Gen Hospital Corp |
Selektion von proteinen unter verwendung von rna- protein-fusionen
|
|
US6261804B1
(en)
|
1997-01-21 |
2001-07-17 |
The General Hospital Corporation |
Selection of proteins using RNA-protein fusions
|
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
|
WO1998048008A1
(en)
|
1997-04-23 |
1998-10-29 |
Plueckthun Andreas |
Methods for identifying nucleic acid molecules encoding (poly)peptides that interact with target molecules
|
|
DE69833755T2
(de)
|
1997-05-21 |
2006-12-28 |
Biovation Ltd. |
Verfahren zur herstellung von nicht-immunogenen proteinen
|
|
US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
US6242195B1
(en)
|
1998-04-02 |
2001-06-05 |
Genentech, Inc. |
Methods for determining binding of an analyte to a receptor
|
|
DE69937291T2
(de)
|
1998-04-02 |
2008-07-10 |
Genentech, Inc., South San Francisco |
Antikörpervarianten und fragmente davon
|
|
AU3463699A
(en)
|
1998-04-03 |
1999-10-25 |
Phylos, Inc. |
Addressable protein arrays
|
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
|
US6846655B1
(en)
|
1998-06-29 |
2005-01-25 |
Phylos, Inc. |
Methods for generating highly diverse libraries
|
|
US20020142374A1
(en)
|
1998-08-17 |
2002-10-03 |
Michael Gallo |
Generation of modified molecules with increased serum half-lives
|
|
JP2002522091A
(ja)
|
1998-08-17 |
2002-07-23 |
フィロス インク． |
３’非翻訳領域を欠損する核酸を生成して細胞ｒｎａ蛋白質融合体形成を最適化する方法
|
|
PT1105360E
(pt)
|
1998-08-17 |
2009-09-30 |
Bristol Myers Squibb Co |
Identificação de interacções entre compostos-proteínas, utilizando bibliotecas de moléculas de fusão entre proteínas-ácidos nucleicos
|
|
ATE354675T1
(de)
|
1998-12-02 |
2007-03-15 |
Adnexus Therapeutics Inc |
Dna-protein fusionen sowie anwendungen derselben
|
|
EP1006183A1
(en)
|
1998-12-03 |
2000-06-07 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Recombinant soluble Fc receptors
|
|
AU776910B2
(en)
|
1998-12-08 |
2004-09-23 |
Merck Patent Gesellschaft Mit Beschrankter Haftung |
Modifying protein immunogenicity
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
KR101077001B1
(ko)
|
1999-01-15 |
2011-10-26 |
제넨테크, 인크. |
효과기 기능이 변화된 폴리펩티드 변이체
|
|
AU779491B2
(en)
|
1999-06-01 |
2005-01-27 |
Bristol-Myers Squibb Company |
Methods for producing 5'-nucleic acid-protein conjugates
|
|
CA2372795A1
(en)
|
1999-07-12 |
2001-01-18 |
Robert G. Kuimelis |
C-terminal protein tagging
|
|
EP1196637B1
(en)
|
1999-07-27 |
2007-04-25 |
Adnexus Therapeutics, Inc. |
Peptide acceptor ligation methods
|
|
JP4803933B2
(ja)
|
1999-08-27 |
2011-10-26 |
ブリストル−マイヤーズ スクウィブ カンパニー |
インビトロ翻訳タンパク質の符号化方法および選別方法
|
|
US7022479B2
(en)
|
2000-01-24 |
2006-04-04 |
Compound Therapeutics, Inc. |
Sensitive, multiplexed diagnostic assays for protein analysis
|
|
DE60118527D1
(de)
|
2000-01-24 |
2006-05-18 |
Compound Therapeutics Inc |
Sensible und multiplexe diagnostische tests zur proteinanalyse
|
|
GB0029407D0
(en)
|
2000-12-01 |
2001-01-17 |
Affitech As |
Product
|
|
PT1355919E
(pt)
|
2000-12-12 |
2011-03-02 |
Medimmune Llc |
Moléculas com semivida longa, composições que as contêm e suas utilizações
|
|
CA2443862A1
(en)
|
2001-04-17 |
2002-10-24 |
Peizhi Luo |
Structure-based construction of human antibody library
|
|
AU2002310502A1
(en)
|
2001-06-21 |
2003-01-08 |
Phylos, Inc. |
In vitro protein interaction detection systems
|
|
JP2005289809A
(ja)
*
|
2001-10-24 |
2005-10-20 |
Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) |
突然変異重鎖抗体
|
|
AU2002365404A1
(en)
|
2001-11-27 |
2003-06-10 |
Compound Therapeutics, Inc. |
Solid-phase immobilization of proteins and peptides
|
|
US20040002587A1
(en)
|
2002-02-20 |
2004-01-01 |
Watkins Jeffry D. |
Fc region variants
|
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
CA2478011C
(en)
|
2002-03-01 |
2013-05-21 |
Immunomedics, Inc. |
Bispecific antibody point mutations for enhancing rate of clearance
|
|
US7425620B2
(en)
|
2002-08-14 |
2008-09-16 |
Scott Koenig |
FcγRIIB-specific antibodies and methods of use thereof
|
|
WO2004029207A2
(en)
|
2002-09-27 |
2004-04-08 |
Xencor Inc. |
Optimized fc variants and methods for their generation
|
|
DK1562972T3
(da)
|
2002-10-15 |
2010-12-06 |
Facet Biotech Corp |
Modifikation af FcRn-bindingsaffiniteter eller serumhalveringstider for antistoffer ved mutagenese
|
|
GB0226729D0
(en)
|
2002-11-15 |
2002-12-24 |
Medical Res Council |
Intracellular antibodies
|
|
EP2368578A1
(en)
|
2003-01-09 |
2011-09-28 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
|
NZ545776A
(en)
|
2003-08-22 |
2009-05-31 |
Biogen Idec Inc |
Improved antibodies having altered effector function and methods for making the same
|
|
GB0324368D0
(en)
|
2003-10-17 |
2003-11-19 |
Univ Cambridge Tech |
Polypeptides including modified constant regions
|
|
CA2545603A1
(en)
|
2003-11-12 |
2005-05-26 |
Biogen Idec Ma Inc. |
Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto
|
|
WO2005077981A2
(en)
|
2003-12-22 |
2005-08-25 |
Xencor, Inc. |
Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
|
|
EP1706424B1
(en)
|
2004-01-12 |
2009-07-22 |
Applied Molecular Evolution, Inc. |
Fc region variants
|
|
US7276585B2
(en)
|
2004-03-24 |
2007-10-02 |
Xencor, Inc. |
Immunoglobulin variants outside the Fc region
|
|
WO2005123780A2
(en)
|
2004-04-09 |
2005-12-29 |
Protein Design Labs, Inc. |
Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
WO2006085967A2
(en)
|
2004-07-09 |
2006-08-17 |
Xencor, Inc. |
OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
|
|
CN103172731A
(zh)
|
2004-07-15 |
2013-06-26 |
赞科股份有限公司 |
优化的Fc变体
|
|
WO2006047350A2
(en)
|
2004-10-21 |
2006-05-04 |
Xencor, Inc. |
IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
|
|
US8460362B2
(en)
|
2006-07-20 |
2013-06-11 |
Orbusneich Medical, Inc. |
Bioabsorbable polymeric medical device
|
|
US20080206585A1
(en)
*
|
2007-02-22 |
2008-08-28 |
Kennametal Inc. |
Composite materials comprising a hard ceramic phase and a Cu-Ni-Mn infiltration alloy
|
|
KR101136262B1
(ko)
|
2007-04-17 |
2012-07-05 |
임클론 엘엘씨 |
ＰＤＧＦＲβ-특이적 억제제
|
|
US20110022149A1
(en)
|
2007-06-04 |
2011-01-27 |
Cox Brian J |
Methods and devices for treatment of vascular defects
|
|
SI2274008T1
(sl)
*
|
2008-03-27 |
2014-08-29 |
Zymogenetics, Inc. |
Sestavki in metode za zaviranje PDGFRBETA in VEGF-A
|
|
EP3629022A1
(en)
*
|
2008-07-25 |
2020-04-01 |
Richard W. Wagner |
Protein screening methods
|
|
EP2496600A1
(en)
*
|
2009-11-04 |
2012-09-12 |
Fabrus LLC |
Methods for affinity maturation-based antibody optimization
|
|
US9880160B2
(en)
*
|
2011-03-15 |
2018-01-30 |
X-Body, Inc. |
Antibody screening methods
|
|
CN102250249A
(zh)
*
|
2011-06-18 |
2011-11-23 |
常州亚当生物技术有限公司 |
一种抗VEGF/PDGFRbeta双特异性抗体及其应用
|
|
JP6483442B2
(ja)
*
|
2011-12-05 |
2019-03-13 |
エックス−ボディ インコーポレイテッド |
Ｐｄｇｆ受容体ベータ結合ポリペプチド
|